4,896 reports of this reaction
3.3% of all LETROZOLE reports
#3 most reported adverse reaction
NEUTROPENIA is the #3 most commonly reported adverse reaction for LETROZOLE, manufactured by Novartis Pharmaceuticals Corporation. There are 4,896 FDA adverse event reports linking LETROZOLE to NEUTROPENIA. This represents approximately 3.3% of all 148,871 adverse event reports for this drug.
Patients taking LETROZOLE who experience neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUTROPENIA is moderately reported among LETROZOLE users, representing a notable but not dominant share of adverse events.
In addition to neutropenia, the following adverse reactions have been reported for LETROZOLE:
The following drugs have also been linked to neutropenia in FDA adverse event reports:
NEUTROPENIA has been reported as an adverse event in 4,896 FDA reports for LETROZOLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUTROPENIA accounts for approximately 3.3% of all adverse event reports for LETROZOLE, making it one of the most commonly reported side effect.
If you experience neutropenia while taking LETROZOLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.